Skip to main content
Erschienen in: Journal of Clinical Immunology 8/2015

01.11.2015 | Original Article

Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection

verfasst von: Cullen M. Dutmer, Edwin J. Asturias, Christiana Smith, Megan K. Dishop, D. Scott Schmid, William J. Bellini, Irit Tirosh, Yu Nee Lee, Luigi D. Notarangelo, Erwin W. Gelfand

Erschienen in: Journal of Clinical Immunology | Ausgabe 8/2015

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Hypomorphic mutations in RAG1 and RAG2 are associated with significant clinical heterogeneity and symptoms of immunodeficiency or autoimmunity may be late in appearance. As a result, immunosuppressive medications may be introduced that can have life-threatening consequences. We describe a previously healthy 13-month-old girl presenting with rash and autoimmune hemolytic anemia, while highlighting the importance of vigilance and consideration of an underlying severe immunodeficiency disease prior to instituting immunosuppressive therapy.

Methods

Given clinical deterioration of the patient and a temporal association with recently administered vaccinations, virus genotyping was carried out via 4 real-time Forster Resonance Energy Transfer PCR protocols targeting vaccine-associated single nucleotide polymorphisms. Genomic DNA was extracted from whole blood and analyzed via the next-generation sequencing method of sequencing-by-synthesis. Immune function studies included immunophenotyping of peripheral blood lymphocytes, mitogen-induced proliferation and TLR ligand-induced production of TNFα. Analysis of recombination activity of wild-type and mutant RAG2 constructs was performed.

Results

Virus genotyping revealed vaccine-strain VZV, mumps, and rubella. Next-generation sequencing identified heterozygosity for RAG2 R73H and P180H mutations. Profound lymphopenia was associated with intense corticosteroid therapy, with some recovery after steroid reduction. Residual, albeit low, RAG2 protein activity was demonstrated.

Conclusions

Because of the association of RAG deficiency with late-onset presentation and autoimmunity, live virus vaccination and immunosuppressive therapies are often initiated and can result in negative consequences. Here, hypomorphic RAG2 mutations were linked to disseminated vaccine-strain virus infections following institution of corticosteroid therapy for autoimmune hemolytic anemia.
Literatur
1.
Zurück zum Zitat Hesslein DG, Schatz DG. Factors and forces controlling V(D)J recombination. Adv Immunol. 2001;78:169–232.CrossRefPubMed Hesslein DG, Schatz DG. Factors and forces controlling V(D)J recombination. Adv Immunol. 2001;78:169–232.CrossRefPubMed
3.
Zurück zum Zitat Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. Science. 1996;274:97–9.CrossRefPubMed Schwarz K, Gauss GH, Ludwig L, Pannicke U, Li Z, Lindner D, et al. RAG mutations in human B cell-negative SCID. Science. 1996;274:97–9.CrossRefPubMed
4.
Zurück zum Zitat Avila EM, Uzel G, Hsu A, Milner JD, Holland SM. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics. 2010;126:1248–52.CrossRef Avila EM, Uzel G, Hsu A, Milner JD, Holland SM. Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics. 2010;126:1248–52.CrossRef
5.
Zurück zum Zitat Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol. 2008;122:1082–6.CrossRefPubMed Villa A, Notarangelo LD, Roifman CM. Omenn syndrome: inflammation in leaky severe combined immunodeficiency. J Allergy Clin Immunol. 2008;122:1082–6.CrossRefPubMed
6.
Zurück zum Zitat de Villartay JP, Lim A, Al-Mousa H, Dupont S, Déchanet-Merville J, Coumau-Gatbois E, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest. 2005;115(11):3291–9.PubMedCentralCrossRefPubMed de Villartay JP, Lim A, Al-Mousa H, Dupont S, Déchanet-Merville J, Coumau-Gatbois E, et al. A novel immunodeficiency associated with hypomorphic RAG1 mutations and CMV infection. J Clin Invest. 2005;115(11):3291–9.PubMedCentralCrossRefPubMed
7.
Zurück zum Zitat Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358:2030–8.CrossRefPubMed Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358:2030–8.CrossRefPubMed
8.
Zurück zum Zitat De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116:1263–71.PubMedCentralCrossRefPubMed De Ravin SS, Cowen EW, Zarember KA, Whiting-Theobald NL, Kuhns DB, Sandler NG, et al. Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood. 2010;116:1263–71.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Kuijpers TW, IJspeert H, van Leeuwen EM, Jansen MH, Hazenberg MD, Weijer KC, et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG. Blood. 2011;117:5892–6.CrossRefPubMed Kuijpers TW, IJspeert H, van Leeuwen EM, Jansen MH, Hazenberg MD, Weijer KC, et al. Idiopathic CD4+ T lymphopenia without autoimmunity or granulomatous disease in the slipstream of RAG. Blood. 2011;117:5892–6.CrossRefPubMed
10.
Zurück zum Zitat Abraham RS, Recher M, Giliani S, Walter JE, Lee YN, Frugoni F, et al. Adult-onset manifestation of idiopathic T-cell lymphopenia due to a heterozygous RAG1 mutation. J Allergy Clin Immunol. 2013;131:1421–3.PubMedCentralCrossRefPubMed Abraham RS, Recher M, Giliani S, Walter JE, Lee YN, Frugoni F, et al. Adult-onset manifestation of idiopathic T-cell lymphopenia due to a heterozygous RAG1 mutation. J Allergy Clin Immunol. 2013;131:1421–3.PubMedCentralCrossRefPubMed
11.
Zurück zum Zitat Henderson LA, Frugoni F, Hopkins G, de Boer H, Pai SY, Lee YN, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013;132:969–71.CrossRefPubMed Henderson LA, Frugoni F, Hopkins G, de Boer H, Pai SY, Lee YN, et al. Expanding the spectrum of recombination-activating gene 1 deficiency: a family with early-onset autoimmunity. J Allergy Clin Immunol. 2013;132:969–71.CrossRefPubMed
12.
Zurück zum Zitat Abolhassani H, Wang N, Aghamohammadi A, Rezaei N, Lee YN, Frugoni F, et al. A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:1375–80.CrossRefPubMed Abolhassani H, Wang N, Aghamohammadi A, Rezaei N, Lee YN, Frugoni F, et al. A hypomorphic recombination-activating gene 1 (RAG1) mutation resulting in a phenotype resembling common variable immunodeficiency. J Allergy Clin Immunol. 2014;134:1375–80.CrossRefPubMed
13.
Zurück zum Zitat Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, et al. RAG1 deficiency may present clinically as selective IgA deficiency. J Clin Immunol. 2015;35:280–8.CrossRefPubMed Kato T, Crestani E, Kamae C, Honma K, Yokosuka T, Ikegawa T, et al. RAG1 deficiency may present clinically as selective IgA deficiency. J Clin Immunol. 2015;35:280–8.CrossRefPubMed
14.
Zurück zum Zitat Lee YN, Frugoni F, Dobbs K, Walter JE, Giliani S, Gennery AR, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol. 2014;133:1099–108.PubMedCentralCrossRefPubMed Lee YN, Frugoni F, Dobbs K, Walter JE, Giliani S, Gennery AR, et al. A systematic analysis of recombination activity and genotype-phenotype correlation in human recombination-activating gene 1 deficiency. J Allergy Clin Immunol. 2014;133:1099–108.PubMedCentralCrossRefPubMed
15.
Zurück zum Zitat IJspeert H, Driessen GJ, Moorhouse MJ, Hartwig NG, Wolska-Kusnierz B, Kalwak K, et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. J Allergy Clin Immunol. 2014;133:1124–33.CrossRefPubMed IJspeert H, Driessen GJ, Moorhouse MJ, Hartwig NG, Wolska-Kusnierz B, Kalwak K, et al. Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. J Allergy Clin Immunol. 2014;133:1124–33.CrossRefPubMed
16.
Zurück zum Zitat Smith C, Dutmer CM, Schmid DS, Bellini WJ, Gelfand EW, Asturias EJ. A toddler with rash, encephalopathy, and hemolytic anemia. J Pediatr Infect Dis. 2015. doi:10.1093/jpids/piv032. Smith C, Dutmer CM, Schmid DS, Bellini WJ, Gelfand EW, Asturias EJ. A toddler with rash, encephalopathy, and hemolytic anemia. J Pediatr Infect Dis. 2015. doi:10.​1093/​jpids/​piv032.
17.
Zurück zum Zitat Asai E, Wada T, Sakakibara Y, Toga A, Toma T, Shimizu T, et al. Analysis of mutations and recombination activity in RAG-deficient patients. Clin Immunol. 2011;138:172–7.CrossRefPubMed Asai E, Wada T, Sakakibara Y, Toga A, Toma T, Shimizu T, et al. Analysis of mutations and recombination activity in RAG-deficient patients. Clin Immunol. 2011;138:172–7.CrossRefPubMed
18.
Zurück zum Zitat Sabry A, Hauk PJ, Jing H, Su HC, Stence NV, Mirsky DM, et al. Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol. 2014;133:1225–7.PubMedCentralCrossRefPubMed Sabry A, Hauk PJ, Jing H, Su HC, Stence NV, Mirsky DM, et al. Vaccine strain varicella-zoster virus-induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency. J Allergy Clin Immunol. 2014;133:1225–7.PubMedCentralCrossRefPubMed
19.
Zurück zum Zitat Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol. 2009;124:522–7.CrossRefPubMed Baker MW, Grossman WJ, Laessig RH, Hoffman GL, Brokopp CD, Kurtycz DF, et al. Development of a routine newborn screening protocol for severe combined immunodeficiency. J Allergy Clin Immunol. 2009;124:522–7.CrossRefPubMed
20.
Zurück zum Zitat Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.PubMedCentralCrossRefPubMed Kwan A, Abraham RS, Currier R, Brower A, Andruszewski K, Abbott JK, et al. Newborn screening for severe combined immunodeficiency in 11 screening programs in the United States. JAMA. 2014;312:729–38.PubMedCentralCrossRefPubMed
21.
Zurück zum Zitat Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. 2015;39:194–205.CrossRefPubMed Kwan A, Puck JM. History and current status of newborn screening for severe combined immunodeficiency. Semin Perinatol. 2015;39:194–205.CrossRefPubMed
22.
Zurück zum Zitat Salt BH, Niemela JE, Pandey R, Hanson EP, Deering RP, Quinones R, et al. IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J Allergy Clin Immunol. 2008;121(4):976–82.PubMedCentralCrossRefPubMed Salt BH, Niemela JE, Pandey R, Hanson EP, Deering RP, Quinones R, et al. IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function. J Allergy Clin Immunol. 2008;121(4):976–82.PubMedCentralCrossRefPubMed
23.
Zurück zum Zitat Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014;133:880–2.PubMedCentralCrossRefPubMed Chen K, Wu W, Mathew D, Zhang Y, Browne SK, Rosen LB, et al. Autoimmunity due to RAG deficiency and estimated disease incidence in RAG1/2 mutations. J Allergy Clin Immunol. 2014;133:880–2.PubMedCentralCrossRefPubMed
24.
Zurück zum Zitat Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.CrossRefPubMed Wardemann H, Yurasov S, Schaefer A, Young JW, Meffre E, Nussenzweig MC. Predominant autoantibody production by early human B cell precursors. Science. 2003;301:1374–7.CrossRefPubMed
25.
Zurück zum Zitat Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, et al. Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol. 2010;125:209–16.CrossRefPubMed Cassani B, Poliani PL, Moratto D, Sobacchi C, Marrella V, Imperatori L, et al. Defect of regulatory T cells in patients with Omenn syndrome. J Allergy Clin Immunol. 2010;125:209–16.CrossRefPubMed
26.
Zurück zum Zitat Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92:223–8.PubMed Dowell SF, Bresee JS. Severe varicella associated with steroid use. Pediatrics. 1993;92:223–8.PubMed
27.
Zurück zum Zitat Russell AF, Parrino J, Fisher Jr CL, Spieler W, Stek JE, Coll KE, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015;33:3129–34.CrossRefPubMed Russell AF, Parrino J, Fisher Jr CL, Spieler W, Stek JE, Coll KE, et al. Safety, tolerability, and immunogenicity of zoster vaccine in subjects on chronic/maintenance corticosteroids. Vaccine. 2015;33:3129–34.CrossRefPubMed
28.
Zurück zum Zitat Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS, et al. Fatal varicella due to the vaccine strain varicella-zoster virus. Hum Vaccin Immunother. 2014;10:146–9.PubMedCentralCrossRefPubMed Leung J, Siegel S, Jones JF, Schulte C, Blog D, Schmid DS, et al. Fatal varicella due to the vaccine strain varicella-zoster virus. Hum Vaccin Immunother. 2014;10:146–9.PubMedCentralCrossRefPubMed
29.
Zurück zum Zitat Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet. 2007;369:1232.CrossRefPubMed Schrauder A, Henke-Gendo C, Seidemann K, Sasse M, Cario G, Moericke A, et al. Varicella vaccination in a child with acute lymphoblastic leukaemia. Lancet. 2007;369:1232.CrossRefPubMed
30.
Zurück zum Zitat Woo EJ. Letter to the editor: fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother. 2015;11:679.CrossRefPubMed Woo EJ. Letter to the editor: fatal varicella due to the vaccine-strain varicella-zoster virus. Hum Vaccin Immunother. 2015;11:679.CrossRefPubMed
31.
Zurück zum Zitat Levy O, Orange JS, Hibberd P, Steinberg S, LaRussa P, Weinberg A, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis. 2003;188:948–53.CrossRefPubMed Levy O, Orange JS, Hibberd P, Steinberg S, LaRussa P, Weinberg A, et al. Disseminated varicella infection due to the vaccine strain of varicella-zoster virus, in a patient with a novel deficiency in natural killer T cells. J Infect Dis. 2003;188:948–53.CrossRefPubMed
32.
Zurück zum Zitat Schuetz C, Neven B, Dvorak CC, Leroy S, Ege MJ, Pannicke U, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123:281–9.PubMedCentralCrossRefPubMed Schuetz C, Neven B, Dvorak CC, Leroy S, Ege MJ, Pannicke U, et al. SCID patients with ARTEMIS vs RAG deficiencies following HCT: increased risk of late toxicity in ARTEMIS-deficient SCID. Blood. 2014;123:281–9.PubMedCentralCrossRefPubMed
Metadaten
Titel
Late Onset Hypomorphic RAG2 Deficiency Presentation with Fatal Vaccine-Strain VZV Infection
verfasst von
Cullen M. Dutmer
Edwin J. Asturias
Christiana Smith
Megan K. Dishop
D. Scott Schmid
William J. Bellini
Irit Tirosh
Yu Nee Lee
Luigi D. Notarangelo
Erwin W. Gelfand
Publikationsdatum
01.11.2015
Verlag
Springer US
Erschienen in
Journal of Clinical Immunology / Ausgabe 8/2015
Print ISSN: 0271-9142
Elektronische ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-015-0207-8

Weitere Artikel der Ausgabe 8/2015

Journal of Clinical Immunology 8/2015 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.